Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

NCT05352893 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG: 750 mg Imsidolimab
DRUG: 300 mg Imsidolimab
OTHER: Placebo

Sponsor

Vanda Pharmaceuticals